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Mycoplasma bovis is a primary infectious agent of many disorders in cattle 
including bovine respiratory disease. No commercial vaccines against M. bovis 
are available in Europe. The immune response of calves to three saponin-based 
adjuvants combined with a field Polish M. bovis strain was evaluated. Four groups 
of six calves each were injected subcutaneously with the M. bovis strain combined 
with either saponin, saponin + Emulsigen®, saponin + Emulsigen® + alpha-
tocopherol acetate, or with phosphate-buffered saline as control group. Blood and 
nasal swab samples were collected up to day 84 post injection. All formulations 
effectively stimulated the humoral and the cellular immune response of the calves, 
but the course of the response depended on the adjuvant formulation. These im-
munological data provide additional information supporting the findings of previ-
ous M. bovis saponin and Emulsigen® vaccine challenge studies to facilitate the 
development of successful M. bovis vaccines. 
Key words: Mycoplasma bovis, cattle, saponin, Emulsigen®, DL-alpha-
tocopherol acetate 
Mycoplasma bovis is an infectious agent of cattle causing bronchopneu-
monia, arthritis and mastitis (Nicholas and Ayling, 2003). It is still widespread in 
Poland, causing economic losses and adversely affecting animal health and wel-
fare (Szacawa et al., 2015). Currently no commercial vaccines against M. bovis 
are available in Europe. However, in some experimental studies treatment with a 
saponin-based bacterin vaccine increased M. bovis-specific antibodies and pro-
tected against a M. bovis challenge in young calves (Nicholas et al., 2002; Dudek 
et al., 2016). The efficacy of a vaccine requires a stimulation of the correct pro-
tective host immune response which depends on the antigenic properties of the 
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mycoplasma isolate and the adjuvant used. Previously some vaccine studies have 
shown a stimulatory effect on humoral immunity but this was often not correlat-
ed with the prevention of M. bovis infection, disease, or colonisation of the upper 
and lower respiratory tract (Maunsell et al., 2009; Soehnlen et al., 2011). Con-
sidering the divergent reports it has been speculated that the cell-mediated im-
munity is necessary to destroy infected cells, and it is likely to be more effective 
in the elimination of M. bovis from the host than the humoral response (Nicholas 
et al., 2017). Information on the course of cellular immune response to M. bovis 
in young calves is limited. It was previously reported that the recall immune re-
sponse to M. bovis lung infection was skewed towards the type 2 T-helper lym-
phocyte cytokine production (Vanden Bush and Rosenbusch, 2003). Immunisa-
tion with M. bovis vaccine showed some cytokine stimulation; however, the re-
sults obtained by different investigators remain ambiguous (Soehnlen et al., 2011; 
Zhang et al., 2014). The adjuvant DL-alpha-tocopheryl-acetate was included as 
part of this study as it is used successfully in some viral, bacterial and Myco-
plasma hyopneumoniae vaccines. 
An understanding of the host immune response and the immunostimulat-
ing effect of antigens with different adjuvants is essential to help formulate an ef-
fective vaccine. Here we investigated the course of the immune response of 
calves to a M. bovis bacterin vaccine consisting of a saponised field Polish M. 
bovis strain on its own, in combination with Emulsigen®, and combined with 
Emulsigen® and DL-alpha-tocopheryl acetate. 
 
 
Materials and methods 
The experimental procedures and animal management protocols were car-
ried out in accordance with the detailed unified requirements of the Local Ethics 
Committee on Animal Experimentation, which also meet the EU standards. 
Animals 
Twenty-four approximately 5-week-old clinically healthy female calves 
were purchased from local farms and delivered to the Institute’s vivarium. After 
a two-week adaptive period the calves were randomly distributed into four 
groups of six calves, with each group housed in individual pens. They were fed 
milk replacer twice a day, and hay and water ad libitum. Before the study, the 
calves had been examined to exclude the presence of M. bovis and Pasteurel-
laceae species using microbiological (Barrow and Feltham, 1993; Nicholas and 
Baker, 1998) and serological methods. For mycoplasma identification, nasal 
swab samples were cultured on Eaton’s broth and agar (Nicholas and Baker, 
1998) and the presence of M. bovis was additionally excluded using the antigenic 
ELISA BIO K 341/2 (Bio-X Diagnostics, Belgium). The calves were also exam-
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ined for specific antibodies against M. bovis (indirect ELISA BIO K 260/2 man-
ufactured by Bio-X Diagnostics, Belgium) and bovine respiratory viruses as de-
scribed by Dudek et al. (2016). 
Suspension of M. bovis and adjuvants  
Polish M. bovis field strain BankIt 1801634 MBovis KP795974 was cul-
tured in a final volume of 25 ml of Eaton’s medium with gentle shaking for total 
of four days at 37 °C with an addition of 5% CO2 (Nicholas and Baker, 1998). 
Then the culture was washed twice in phosphate-buffered saline (PBS, pH 7.2) 
and centrifuged at 10,000 × g for 40 min. The supernatant was finally discarded 
and the washed mycoplasma cells were mixed with 2 mg/ml saponin (Sigma, 
Poole) as described previously (Nicholas et al., 2002). In the mycoplasma cells–
saponin mix the final titre of mycoplasma cells was 1.0 × 108 CFU/ml. For the 
S+E and S+E+T groups 2 ml of Emulsigen® (MVP Laboratories, Inc. Ralston, 
Nebraska, USA) was added to 5 ml of the mycoplasma cells-saponin mix. Finally, 
3 ml of PBS (pH 7.2) was added to the S; and 1 ml to the S+E adjuvant, and 1 ml 
of DL-alpha-tocopheryl acetate (Merck Millipore, 500 mg/ml) was added for the 
S+E+T adjuvant. A final concentration of 6.25 × 107 CFU/ml was quantified in 
all of the adjuvants being tested. The CFU count was calculated according to the 
OD quantification method described by Ayling et al. (2000) and confirmed by 
carrying out dilution counts according to Postgate (1969). The vaccine formula-
tions were checked to be free of mycoplasma and bacteria contamination by cul-
turing on Eaton’s and blood agar (Nicholas et al., 2002). A final volume of 8 ml 
of each mycoplasma adjuvant mix was used for each calf.  
Injection of calves 
Each of the six calves in the four groups were administered 8 ml subcuta-
neously in the neck, as per their assigned group, with either S, S+E, S+E+T, or 
PBS for the control group (C). 
Clinical observations 
The calves were observed throughout the experimental period. Rectal 
temperatures, any nasal discharge and non-specific local postvaccinal reactions 
(oedema, pain, etc.) were recorded early every morning before feeding milk re-
placer and performed for days 0 to 7 at the beginning of the study, and then at 
weekly intervals up to day 84 post injection. 
Samples 
Nasal swabs and blood samples were collected daily from all calves on 
days 0 to 7, and then at weekly intervals up to day 84 post injection. For haema-
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tological as well as CD2,4,8 and WC4 antigen analyses the whole blood samples 
were collected into a 1-ml vacutainer with EDTA-K2 anticoagulant, whereas for 
serological analyses the whole blood samples were collected into serum separa-
tor tubes, centrifuged at 1500 g at 18–25 °C for 10 min to obtain sera, and then 
stored at –20 °C until analysed. 
Mycoplasma bovis antigen 
Mycoplasma bovis was detected in nasal swabs using the antigenic ELISA 
BIO K 341/2 (Bio-X Diagnostics, Belgium) according to the manufacturer’s in-
structions. 
Anti-Mycoplasma bovis specific antibodies 
Blood samples were examined for the presence of specific antibodies to 
M. bovis using indirect ELISA BIO K 260/2 manufactured by Bio-X Diagnostics 
(Belgium) according to the manufacturer’s instructions. 
Blood leukocyte counts 
Total white blood cell (WBC) counts with differentiation of polymorpho-
nuclear leukocytes (GRA), lymphocytes (LYM) and monocytes (MON) were ob-
tained using an automatic veterinary blood analyser (Exigo, Boule Medical AB, 
Sweden). 
CDs and WC4 antigens 
The percentages of peripheral blood lymphocytes such as T-cell (CD2+), 
T-helper cell (CD4+, Th), T-cytotoxic suppressor cell (CD8+, Tc/s) and B-cell 
(WC4+) antigens were determined using a flow cytometer (Coulter Epics XL 4C, 
Beckman Coulter Company, USA). The expression of the CD markers was de-
termined using primary mouse anti-bovine monoclonal antibodies and for WC4+ 
expression additionally by the use of rabbit anti-mouse secondary polyclonal an-
tibody (AbD Serotec, a Bio-Rad Company) as described by Dudek et al. (2015). 
Acute phase protein, IL-4 and IFN-γ concentrations 
Commercial kits were used to determine acute phase proteins (APPs): hap-
toglobin (Hp) and serum amyloid A (SAA) (Tridelta Development Limited, Ire-
land) and the cytokines interferon-gamma (IFN-γ, ID.vet Innovative Diagnostics, 
France) and interleukin-4 (IL-4, USCN Life Science, Inc., Houston, USA). 
Acute phase protein and cytokine concentrations, M. bovis antigen and 
specific antibodies to M. bovis, BHV1, BVDV, BRSV and PI3V were deter-
mined according to the individual ELISA procedures using an automated plate 
reader (Elx800 Microplate Reader, BioTek Instruments, Inc., USA). 
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IL-6, TNF-α, IL-10 and IL-12 concentrations 
Directly before analysis samples were defrosted at 4 °C and then diluted 
1:5 in PBS pH 7.0 (Sigma-Aldrich), as previously optimised. Six populations of 
microbeads (BD Biosciences) with distinctive fluorescence coated with mono-
clonal antibody for IL-6, TNF-α, IL-10, IL-12(p40) and IL-12(p70) were used 
during cytometric analysis. Standards for the examined cytokines (BD Biosci-
ence) were prepared according to the manufacturer’s instruction. To 50 μl of mi-
crobeads mix (diluted 1:50; BD Biosciences) 50 μl of each sample was added, 
incubated at 18–25 °C for 1 h. Then 50 μl of the detection mix (antibodies con-
jugated with PE, diluted 1:50, BD Biosciences) was added and incubated for 2 h 
in the dark. Microbeads were washed with 1 ml of PBS pH 7.0 (Sigma-Aldrich), 
centrifuged at 300 g for 10 min and suspended in 300 μl of PBS. The samples 
were analysed using a flow cytometer (Navios, Beckman Coulter Company, USA) 
at 576 nm (PE), 660 nm (APC) and 680 nm (APC/Cy7). The cytokine concentra-
tions were calculated on the basis of standard curves. The final results were giv-
en in pg/ml after calculating the dilution factor. 
Statistical analysis 
Arithmetic means ± standard deviation were calculated with differences 
between the mean values of the groups at the same time point, and analysed us-
ing the t test with a P < 0.05 level of statistical significance. 
 
 
Results 
The vaccine formulations had no bacterial contamination and no myco-
plasma or Pasteurellaceae species were isolated from any of the nasal swabs of 
calves. No seroconversion to the respiratory viruses BHV-1, BVDV, BRSV and 
PI3V was observed. 
Clinical observations  
At day one post injection of the vaccine formulations the rectal tempera-
ture of all the calves was above the normal range (40.4–41.1 °C). By day 2 just 
two calves in the S+E group and one calf in each of the S and S+E+T group had 
an elevated temperature. At days 3 and 4 the same calf in each of the S+E and 
S+E+T groups had an elevated temperature. At day 5 only the S+E calf had a 
slightly raised temperature but it was below 40.0 °C. Otherwise the animals’ 
body temperatures, including those of the group C calves, were within the nor-
mal range (37.5–39.5 °C) throughout the study. 
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One calf from the S+E+T group had a mucous nasal discharge at day 6. A 
slight oedema at the site of injection was seen in some calves for a few weeks 
from day one post vaccination. 
Anti-M. bovis antibodies 
Specific M. bovis antibodies first appeared at day 7 and were raised until 
week 24 in all of the vaccinated calves, with the controls remaining negative. 
The S+E+T group had the highest percent (%) at week 9; however, the titre of 
the S+E group persisted at a higher level throughout the experiment (Fig. 1). 
 
Fig. 1. Anti-Mycoplasma bovis specific antibodies of calves vaccinated with the M. bovis strain 
combined with either: saponin (S), saponin + Emulsigen® (S+E,) saponin + Emulsigen® + alpha-
tocopherol acetate (S+E+T). a: significant differences at P < 0.05 between Groups C and S;  
b: between Groups C and S+E; c: between Groups C and S+E+T. Val, %: value expressed in  
percentage, obtained by dividing the signal read (OD) for the sample by the signal read (OD)  
for the positive control serum and multiplying the result by 100. A sample is considered positive if 
the Val is higher than 37% 
Blood leukocyte counts 
For all of the vaccine formulations, the WBC (Fig. 2a), GRA (Fig. 2b) and 
MID (Fig. 2d) counts increased compared to the control group at day 1 post in-
jection. These counts then fell for all the experimental groups, giving comparable 
or lower values than the controls for most study days. The most evident GRA 
rise was observed in the S+E+T group. 
The LYM count in the S group had comparable values to the control 
throughout the study, whereas in the other groups it was lower than the control 
for most study days (Fig. 2c). 
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Fig. 2. Total white blood cell (WBC) count (2A) and WBC counts with differentiation of polymor-
phonuclear leukocytes (GRA, 2B), lymphocytes (LYM, 2C) and monocytes (MON, 2D) of calves 
vaccinated with the Mycoplasma bovis strain combined with either: saponin (S), saponin + Emulsi-
gen® (S+E,) saponin + Emulsigen® + alpha-tocopherol acetate (S+E+T). a: significant differences 
at P < 0.05 between Groups C and S; b: between Groups C and S+E; c: between Groups C and 
S+E+T 
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CDs and WC4 antigens 
Throughout most of the study the CD2+ (Fig. 3a), CD4+ (Fig. 3b) and 
CD8+ (Fig. 3c) percent increase was most evident in the S+E group compared to 
the controls, whereas the values of the other groups were comparable to the con-
trols, with the exception of day 6 for CD2+ when a significant rise was observed 
in the S+E+T group. 
The WC4+ percent was stimulated earliest in the S group compared to the 
control; however, it was higher than the control in both the S and S+E groups be-
tween days 5 and 35 post injection. This stimulation was prolonged in the S+E 
group until day 49. In the S+E+T group this percent was increased compared to 
the control between days 14 and 21, and also at days 35 and 49 post injection. 
However, the WC4+ percent was higher in all of the experimental groups than in 
the control between days 77 and 84 (Fig. 3d). 
Hp, SAA, IFN-γ and IL-4 concentrations 
The Hp concentration was increased in all of the vaccinated groups. How-
ever, this rise was most evident in the S+E+T group until day 5 (Fig. 4a). The 
SAA concentration was increased in all the vaccinated groups until day 7 post in-
jection. It was most evident in the S group at day 1 and more visible in the S+E 
and S+E+T groups at day 2 with the S+E group peaking again at days 14 and 42 
(Fig. 4b). The IFN-γ concentration increased in all of the vaccinated groups until 
day 3 and then at days 4 and 7 in the S+E and S+E+T groups, and additionally in 
the S+E group at day 56 and for all vaccinated groups at day 77 (Fig. 4c). 
The IL-4 concentration was increased in the S+E+T group at days 14 and 
21, whereas in the S+E group it was higher than in the control group at days 7, 
21, 63 and 70. Throughout the study the values of the S group were comparable 
to those of the control group (Fig. 4d). 
IL-6, TNF-α, IL-10 and IL-12 concentrations 
The IL-6 concentration was increased in the S+E group throughout the 
study. In the S and S+E+T groups it was comparable to the control with the ex-
ception of day 84 when a significant drop in the IL-6 concentration was observed 
(Fig. 5a). The TNF-α and IL-10 concentrations in all of the vaccinated groups 
were comparable to the controls with the exception of day 56 when a TNF-α in-
crease was observed especially in the S+E group (Fig. 5b) and an IL-10 decrease 
in the S group (Fig. 5c). The IL-12p70 concentration in the S group was compa-
rable to that in the controls. In the other vaccinated groups it was higher than in 
the controls throughout the study; however, this rise was most evident in the S+E 
group (Fig. 5d). The IL-12p40 concentration in all of the vaccinated groups was 
comparable to the controls, with the exception of day 28 in the S+E group and 
day 56 in the S group when a visible rise was observed (Fig. 5e). 
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Fig. 3. CD2+ (3A), CD4+ (3B), CD8+ (3C) and WC4+ (3D) percentages of calves vaccinated with 
the Mycoplasma bovis strain combined with either: saponin (S), saponin + Emulsigen® (S+E,)  
saponin + Emulsigen® + alpha-tocopherol acetate (S+E+T). a: significant differences at P < 0.05 
between Groups C and S; b: between Groups C and S+E; c: between Groups C and S+E+T 
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Fig. 4. Haptoglobin (Hp, 4A), serum amyloid A (SAA, 4B), interferon-gamma (IFN-γ, 4C) and  
interleukin-4 (IL-4, 4D) concentrations of calves vaccinated with the Mycoplasma bovis strain 
combined with either: saponin (S), saponin + Emulsigen® (S+E,) saponin + Emulsigen® + alpha-
tocopherol acetate (S+E+T). a: significant differences at P < 0.05 between Groups C and S;  
b: between Groups C and S+E; c: between Groups C and S+E+T  
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Fig. 5. IL-6 (5A), tumour necrosis factor-alpha (TNF-α, 5B), IL-10 (5C), IL-12p70 (5D) and IL-
12p40 (5E) concentrations of calves vaccinated with the Mycoplasma bovis strain combined with 
either: saponin (S), saponin + Emulsigen® (S+E,) saponin + Emulsigen® + alpha-tocopherol  
acetate (S+E+T). a: significant differences at P < 0.05 between Groups C and S;  
b: between Groups C and S+E; c: between Groups C and S+E+T  
 
 
Discussion 
In this study, the stimulation of the systemic humoral immune response 
following the injection of different saponin-based adjuvant formulations com-
bined with the field M. bovis strain was observed. All of the tested formulations 
effectively stimulated the production of specific antibodies to M. bovis which 
was observed from week 2 post injection. This stimulation lasted until week 24, 
which is consistent with the findings of our previous study (Dudek et al., 2016). 
A correlation between the stimulation of humoral immunity and the protective 
effect of saponin-adjuvanted bacterin vaccines was reported previously (Nicholas 
et al., 2002; Dudek et al., 2016). 
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Considering the divergent opinions about the role of the humoral response 
in preventing M. bovis infections it is suggested that the cellular immunity is 
likely to be more effective in eliminating M. bovis from the host than the humor-
al response (Nicholas et al., 2017). In this study all of the tested saponin-based 
adjuvants appeared to enhance the cell-mediated immune response but this de-
pended on the adjuvant formulation. The leukocytosis visible on day 1 post in-
jection for all of the tested adjuvant formulations was probably the result of mo-
bilisation of the blood immune cells, whereas general lymphopenia observed for 
most days of the study resulted from lymphocyte recirculation. The stimulation 
of the T-cell response following the injection of all of the tested saponin adju-
vants was reflected in the increase of both the Th and T c/s cells. However, the 
most evident Th cell response was observed in the S+E group, whereas a strong-
er stimulation of Tc/s cells was shown in the remaining experimental groups. It is 
known that cytokines secreted by Th lymphocytes play a role in the differentia-
tion of B lymphocytes into the pool of plasmatic cells secreting antibodies (Her-
meyer et al., 2012). In this study the most evident B-cell response and the 
strongest stimulation of the M. bovis-specific antibodies were in the S+E group. 
A general stimulation of the CD4+ and WC4+ cells to an M. bovis infection was 
indicated previously, regardless of the isolate used as a challenge (Dudek et al., 
2015). Vanden Bush and Rosenbusch (2003) demonstrated that the recall im-
mune response to M. bovis is skewed towards a Th2 response which resulted 
from a dominant IL-4 response. The activation of both the CD4+ and CD8+ cells 
was also reported (Vanden Bush and Rosenbusch, 2003). It is known that IL-4 
plays an important role in B-cell differentiation (Estes et al., 1995). In contrast to 
the Th2 response, the Th1 response is characterised by an increase in IFN-γ with 
no IL-4 response (Estes et al., 1995; Vanden Bush and Rosenbusch, 2003). In 
another study, significant stimulation of IFN-γ concentration was observed with 
all of the saponin-based adjuvant formulations. In that study the IL-4 response 
was poor and observed on just a few days which may suggest that the immune 
response to saponin-based M. bovis vaccine is characterised by a Th1-skewed cy-
tokine production or it is a slightly mixed Th-1–Th-2 cytokine response. This 
hypothesis could also be confirmed by a lack of significant changes in the con-
centration of IL-10, one of the cytokines associated with the Th2 response, fol-
lowing immunisation with all of the saponin-based adjuvants (O’garra and Vieira, 
2004; Saraiva and O’Garra, 2010). In contrast, specifically in the S+E group, a 
stimulation of the production of IL-12, i.e. of the cytokine which is crucial for 
the induction of the Th1 response, was recorded (Farias et al., 2016). In this 
study a stimulation of IL-6 and TNF-α production was observed in all of the vac-
cinated groups, but the response varied with the different adjuvant formulations. 
However, the most evident cytokine stimulation was recorded in the S+E group. 
IL-6 and TNF-α are known to be pro-inflammatory cytokines. It was previously 
reported that TNF-α and IFN-γ are key cytokines for the induction of other cyto-
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kines, e.g. IL-6 (van Miert, 1995). Whilst IL-6 is responsible for depressing 
TNF-α production, it also has an antagonistic effect on IL-10 with regard to IL-6 
production (Schindler et al., 1990; Knolle et al., 1995). However, an increased 
IL-6 and TNF-α concentration observed previously stabilised in all of the vac-
cinated groups on day 84. In comparison, the two commercially available M. bo-
vis bacterin vaccines did not have a significant effect on the serum concentra-
tions of the screened cytokines including IL-1β, IL-2, IL-4, IL-6, IFN-γ or TNF-
α (Soehnlen et al., 2011). However, Zhang et al. (2014) showed that in response 
to two live attenuated M. bovis vaccines TNF-α levels were not detectable. Fur-
ther studies using wider cytokine profiles are required to increase our under-
standing of these interrelated responses. 
Previously Dudek et al. (2011a, 2013) reported that M. bovis activated the 
acute phase response (APR) and the saponin-based adjuvant formulations effec-
tively stimulated Hp and SAA production. Some cytokines, including IL-6 and 
TNF-α, act as mediators of the production of APPs during APR (Heinrich et al., 
1990; Gruys et al., 2005). The increased IL-6 production observed in the S+E 
group at the beginning of the study may have been responsible for stimulating 
the concentration of the examined APPs. Hp and SAA are known as major bo-
vine APPs and were previously recognised as effective indicators of bovine 
health and disease (Ceciliani et al., 2012). It is known that human SAA has 
chemotactic activity towards polymorphonuclear leukocytes and monocytes but 
this function is still under investigation in cattle (Badolato et al., 1994). The few 
days of increased SAA concentration could be associated with leukocyte re-
cruitment and further their migration, adhesion and infiltration of target tissues, 
as has been described in a human model (Badolato et al., 1994). Modulating the 
immunological functions of leukocytes facilitates avoidance of the host’s im-
mune system. Mycoplasma bovis can inhibit the bovine neutrophil respiratory 
burst, which is known to be a major antimicrobial mechanism associated with the 
production of reactive oxygen species (ROS) (Thomas et al., 1991; Fang, 2004). 
A reported function of SAA is the inhibition of oxidative burst response in hu-
man neutrophils and that the SAA counteracts responses of these cells to cyto-
kines or bacteria, which may prevent oxidative destruction of the tissues by ROS 
(Linke et al., 1991). Therefore, the observed initial stimulation of SAA concen-
tration supports a beneficial effect of the tested vaccines. 
Mycoplasma bovis is able to cause inflammation within various bovine or-
gans (Nicholas and Ayling, 2003). An infection with these bacteria may lead to the 
activation of alveolar macrophages resulting in neutrophil migration to the tar-
geted tissues and release of proinflammatory mediators (Maunsell et al., 2011). 
Mycoplasma bovis may activate the synthesis of some arachidonic acid metabo-
lites (Dudek et al., 2011b). Haptoglobin is also known to inhibit the respiratory 
burst activity of human neutrophils as a result of stimulation of diverse agonists, 
e.g. arachidonic acid (Oh et al., 1990). Considering these anti-inflammatory ac-
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tivities of Hp, its observed initial stimulation post injection appears to indicate a 
beneficial effect of the M. bovis strain and adjuvant combination. 
All saponin-based formulations effectively stimulated the humoral and 
cellular immune response in the calves. This further supports the use of saponin 
and Emulsigen® as demonstrated successfully in a challenge study (Dudek et al., 
2016). 
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